AMRI Expands R&D and Manufacturing Sites

Published on: 

AMRI will increase R&D and manufacturing capabilities for orphan and rare disease products.

Albany Molecular Research, Inc. (AMRI) announced on April 30, 2021 that it has expanded its contract research, development, and manufacturing capabilities for orphan and rare disease products.

The expansion will include additional suites at its Albany, NY, facility for the manufacturing of batch sizes of 10–15 kilograms; expanded hydrogenation, filtering, drying, and analytical capabilities, along with added liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry instruments at its Grafton, Wis., facility; and formulation development and clinical sterile drug product manufacturing capabilities at its Glasgow, Scotland site, AMRI said in a company press release.

“AMRI is committed to making a difference for the innovators that meet the challenges of orphan drugs and, in turn, for the patients living with rare diseases,” said John Ratliff, CEO, AMRI, in the press release. “AMRI’s scientists and operators dedicate both hearts and minds to these programs, including our regulatory and intellectual property professionals who work closely alongside customers to navigate the complex landscape associated with orphan designations and our scientists who can manage the complexity of these innovative products. Our teams deliver seamless programs for orphan products from R&D through manufacturing with a passionate commitment to ‘right first time’ throughout.”


Source: AMRI